Physician profile
Melissa Maria Erickson
NPI 1730356056
$221,302.01
in general payments reported to CMS, 2019-2025
22 companies · $35K in 2025
The $35K reported for 2025 was more than what 94% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,019 · 2020: $4,927 · 2021: $11K · 2022: $105K · 2023: $51K · 2024: $12K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $51K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Travel and Lodging: $13K · Food and Beverage: $5,131 · Royalty Or License: $589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $50,926.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,425.00 |
| Travel and Lodging | $12,881.76 |
| Food and Beverage | $5,130.82 |
| Royalty Or License | $588.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $110,192.78 | 2021-2025 | Cd Horizon Spinal System, Stealthstation S8 Platform, Mazor X System |
| Medical Device Business Services, INC. | $48,189.48 | 2019-2025 | Viper, Conduit, Expedium Verse |
| Globus Medical, INC. | $43,368.44 | 2019-2025 | Excelsius Gps, Rise-L . Rise-L A/L, Xlif |
| Restor3d, INC. | $8,459.36 | 2023-2024 | |
| Alphatec Spine, INC | $4,499.12 | 2025 | Other - Miscellaneous, Invictus Open |
| Depuy Synthes Sales INC. | $2,115.02 | 2019-2025 | Viper, Teligen, Conduit |
| Integrity Implants INC. | $1,258.98 | 2021 | |
| Tricoast Surgical Solutions LLC | $662.27 | 2025 | |
| Si-Bone, INC. | $453.53 | 2019-2025 | |
| Centinel Spine, LLC | $393.04 | 2022-2024 | Prodisc L |
| Medicrea USA, Corp. | $263.81 | 2019 | |
| Arthrex, INC. | $257.49 | 2025 | |
| Medtronic USA, INC. | $213.29 | 2019 | |
| Brainlab, INC. | $202.29 | 2021-2025 | Brainlab, INC. |
| Cerapedics INC. | $157.28 | 2022-2025 | I-Factor Peptide Enhanced Bone Graft |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nuvasive, INC. | $154.21 | 2019 | |
| Bioventus LLC | $108.30 | 2023 | Bonescalpel |
| Lifenet Health | $95.41 | 2025 | Pliafx Flo |
| Stryker Corporation | $90.67 | 2021-2022 | |
| Zimmer Biomet Holdings, INC. | $89.17 | 2019 | |
| Innovation Technologies INC | $71.64 | 2020 | |
| Trackx Technology, INC. | $6.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$30,367.12 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Erickson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.